Ocular Therapeutix (NASDAQ:OCUL) Price Target Raised to $28.00

Ocular Therapeutix (NASDAQ:OCUL) had its target price raised by HC Wainwright from $25.00 to $28.00 in a report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Ocular Therapeutix’s Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.62) EPS, Q1 2027 earnings at ($0.47) EPS, Q2 2027 earnings at ($0.47) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.87) EPS.

Several other equities analysts have also commented on OCUL. Needham & Company LLC reissued a “buy” rating and set a $18.00 price target on shares of Ocular Therapeutix in a research report on Monday, October 19th. Chardan Capital reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Ocular Therapeutix in a research report on Friday, October 2nd. Royal Bank Of Canada reiterated an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, September 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Thursday, October 15th. Finally, UBS Group initiated coverage on shares of Ocular Therapeutix in a research report on Sunday, October 11th. They set a “buy” rating and a $14.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.83.

Ocular Therapeutix Trading Down 5.7%

Shares of OCUL opened at $6.28 on Tuesday. The stock’s 50-day moving average is $8.08 and its two-hundred day moving average is $8.93. Ocular Therapeutix has a 12 month low of $6.00 and a 12 month high of $16.44. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.03 and a current ratio of 9.12.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.06). Ocular Therapeutix had a negative return on equity of 59.95% and a negative net margin of 648.64%. The company had revenue of $12.87 million during the quarter, compared to analysts’ expectations of $14.27 million. During the same period in the previous year, the company earned ($0.38) EPS. Ocular Therapeutix’s quarterly revenue was down 11.5% on a year-over-year basis. On average, research analysts anticipate that Ocular Therapeutix will post -1.58 earnings per share for the current fiscal year.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Todd Anderman sold 11,984 shares of the business’s stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $7.29, for a total value of $87,363.36. Following the transaction, the insider owned 140,484 shares in the company, valued at approximately $1,024,128.36. The trade was a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Namrata Saroj sold 35,370 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $6.55, for a total value of $231,673.50. Following the completion of the transaction, the insider directly owned 220,522 shares of the company’s stock, valued at $1,444,419.10. This represents a 13.82% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 98,090 shares of company stock valued at $787,920. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Ocular Therapeutix

Hedge funds and other institutional investors have recently bought and sold shares of the business. Private Advisor Group LLC bought a new stake in shares of Ocular Therapeutix in the 3rd quarter worth about $130,000. CenterBook Partners LP acquired a new stake in shares of Ocular Therapeutix in the 3rd quarter valued at about $233,000. Kraematon Investment Advisors Inc. lifted its position in shares of Ocular Therapeutix by 6.9% during the third quarter. Kraematon Investment Advisors Inc. now owns 117,517 shares of the biopharmaceutical company’s stock worth $901,000 after purchasing an additional 7,550 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in shares of Ocular Therapeutix by 8.1% during the third quarter. Commonwealth Equity Services LLC now owns 20,992 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 1,575 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ocular Therapeutix during the third quarter worth about $86,000. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Latest Ocular Therapeutix News

These are some of the OCUL news items that stood out recently:

• Positive Sentiment: Coverage highlighted Phase 3 success in wet AMD, which could strengthen the outlook for Ocular Therapeutix’s pipeline. Investors are also weighing how much of that potential is reflected in the stock’s valuation. Article: How Investors Are Reacting To Ocular Therapeutix (OCUL) Phase 3 Wet AMD Success
• Neutral Sentiment: RBC Capital kept its Buy rating, offering support for the bullish analyst view but not representing a new rating change. Article: RBC Capital Keeps Their Buy Rating on Ocular Therapeutix
• Negative Sentiment: HC Wainwright cut its loss-per-share forecasts across late 2026 and 2027, including FY2026 to ($1.62) from ($1.49) and FY2027 to ($1.87) from ($1.54). The revisions suggest expectations for deeper losses, tempering the optimism from the trial news.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.